The generics are less flashy investments as compared to biotechnology companies. However, they also carry much less risk and offer steady growth to investors.
The solar industry a highly competition space with ample growth opportunities but SunEdison needs to focus on balance sheet problems from now.
Let's take a look at how Sequenom has bounced back recently.
A look at biotech company Inovio and its future prospects.
A close look at Opko Health.